Bivalirudin: A review of pharmacology and therapeutic use

Connecticut Medicine

Volumn 74, Issue 10, 2010, Pages 595-597

  Scholle, Jennifer M ^a,b   White, C Michael ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

CLINICAL TRIAL (TOPIC); HUMAN; REVIEW;

ANTITHROMBINS; CLINICAL TRIALS AS TOPIC; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS;

EID: 79952276334     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ruberg F, Leopold J, Loscalzo J.: Atherothrombosis: Plaque instability and thrombogenesis. Prog Cardiovasc Dis 2003; 44: 381-94.
2. Fox I, Dawson A, Loynds, et al.: Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63.
3. Witting JI, Bourdon P, Brezniak D.V., et al.: Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biocbem J 1992; 283: 737-43.
4. The Medicines Company: Angiomax (bivalirudin) package insert. Cambridge, MA 2000.
5. McEvoy GK (Ed): AHFS Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc.: 2010.
6. Eitzman DT, Chi L, Saggin L., et al.: Heparin neutralization by platelet-rich thrombi: Role of platelet factor 4. Circulation 1994; 82: 1193-202.
7. Anderson JL, Adams CD, Antman E.M., et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Academic Emergency Medicine. Circ 2007; 116: e148-304.
8. Bittl JA, Strony J, Brinker J.A., et al.: Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995; 333: 764-9.
9. Bittl JA, Chaitman BR, Feit T, et al.: Bivalirudin vs heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am J Heart J 2001; 142: 952-9.
10. Lincoff AM, Bitd JA, Harrington R.A., et al: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 2003; 289: 853-63.
11. Stone GW, McLaurin BT, Cox D.A., et al.: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-16.
12. Stone GW, White HD, Ohman E.M., et al.: Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907-19.
13. Stone GW, Witzenbichler B, Guagliumi G., et al.: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358: 2218-30.